A Systems Biology Approach Provides Deeper Insights into Differentially Expressed Genes in Taxane-Anthracycline Chemoresistant and Non-Resistant Breast Cancers

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 Oct 27

PMID 29072056

Citations 4

Authors

Shamim Sarhadi

Somayeh Sadeghi

Fatemeh Nikmanesh

Younes Pilehvar Soltanahmadi

Arman Shahabi

Sedigheh Fekri Aval

Nosratollah Zarghami

Affiliations

Soon will be listed here.

Abstract

Objective: To date, numerous studies have been conducted to search for reasons for chemoresistance and differences in survival rates of patients receiving chemotherapy. We have sought to identify differentially expressed genes (DEGs) between predicted chemotherapy resistance and sensitive phenotypes by a network as well as gene enrichment approach. Methods: Functional modules were explored with network analysis of DEGs in predicted neoadjuvant taxane-anthracycline resistance versus sensitive cases in the GSE25066 dataset, including 508 samples. A linear model was created by limma package in R to establish DEGs. Results: A gene set related to phagocytic vesicle membrane was found to be up-regulated in chemoresistance samples. Also, we found GO_CYTOKINE_ACTIVITY and GO_GROWTH_FACTOR BINDING to be up-regulated gene sets with the chemoresistance phenotype. Growth factors and cytokines are two groups of agents that induce the immune system to recruit APCs and promote tolerogenic phagocytosis. Some hub nodes like S100A8 were found to be important in the chemoresistant tumor cell network with associated high rank genes in GSEA. Conclusions: Functional gene sets and hub nodes could be considered as potential treatment targets. Moreover, by screening and enrichment analysis of a chemoresistance network, ligands and chemical agents have been found that could modify significant gene sets like the phagocytic vesicle membrane functional gene set as a key to chemoresistance. They could also impact on down- or up-regulated hub nodes.

Citing Articles

Transcriptomic analysis revealed potential regulatory biomarkers and repurposable drugs for breast cancer treatment.

Shornale Akter M, Uddin M, Rahman S, Hossain M, Ashik M, Zaman N Cancer Rep (Hoboken). 2024; 7(5):e2009.

PMID: 38717954 PMC: 11078332. DOI: 10.1002/cnr2.2009.

Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach.

Vyas B, Kumar S, Bhowmik R, Akhter M Sci Rep. 2023; 13(1):13729.

PMID: 37607964 PMC: 10444824. DOI: 10.1038/s41598-023-40684-7.

Formulation of Genistein-HP β Cyclodextrin-Poloxamer 188 Ternary Inclusion Complex: Solubility to Cytotoxicity Assessment.

Zafar A, Alruwaili N, Imam S, Alsaidan O, Alkholifi F, Alharbi K Pharmaceutics. 2021; 13(12).

PMID: 34959278 PMC: 8707042. DOI: 10.3390/pharmaceutics13121997.

Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression.

Rasouli S, Zarghami N Asian Pac J Cancer Prev. 2018; 19(4):977-982.

PMID: 29693804 PMC: 6031784. DOI: 10.22034/APJCP.2018.19.4.977.

References

Moreira M, Bagni C, Pinho M, Mac-Cormick T, dos Santos Mota M, Pinto-Silva F . Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line. Leuk Res. 2014; 38(8):983-7. DOI: 10.1016/j.leukres.2014.06.001. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Ou Y, Guo X . [Tumor stem cells and drug resistance]. Sheng Li Ke Xue Jin Zhan. 2007; 38(2):115-9. View

Javan Maasomi Z, Pilehvar Soltanahmadi Y, Dadashpour M, Alipour S, Abolhasani S, Zarghami N . Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells. Asian Pac J Cancer Prev. 2017; 18(5):1283-1287. PMC: 5555536. DOI: 10.22034/APJCP.2017.18.5.1283. View

Eatemadi A, Daraee H, Aiyelabegan H, Negahdari B, Rajeian B, Zarghami N . Synthesis and Characterization of Chrysin-loaded PCL-PEG-PCL nanoparticle and its effect on breast cancer cell line. Biomed Pharmacother. 2016; 84:1915-1922. DOI: 10.1016/j.biopha.2016.10.095. View

Yang X, Zhang M, Zhou Q, Wu S, Zhao Y, Gu W . High expression of S100A8 gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway. Onco Targets Ther. 2016; 9:4887-99. PMC: 4982505. DOI: 10.2147/OTT.S101594. View

Eatemadi A, Darabi M, Afraidooni L, Zarghami N, Daraee H, Eskandari L . Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines. Artif Cells Nanomed Biotechnol. 2015; 44(3):1008-17. DOI: 10.3109/21691401.2015.1008510. View

Hsu Y, Hung J, Tsai E, Wu C, Ho Y, Jian S . Benzyl butyl phthalate increases the chemoresistance to doxorubicin/cyclophosphamide by increasing breast cancer-associated dendritic cell-derived CXCL1/GROα and S100A8/A9. Oncol Rep. 2015; 34(6):2889-900. DOI: 10.3892/or.2015.4307. View

Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H . The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13):5405-13. DOI: 10.1158/0008-5472.CAN-07-5206. View

10.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

11.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

12.

Abdullah L, Chow E . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2(1):3. PMC: 3565873. DOI: 10.1186/2001-1326-2-3. View

13.

Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M . GeneCards Version 3: the human gene integrator. Database (Oxford). 2010; 2010:baq020. PMC: 2938269. DOI: 10.1093/database/baq020. View

14.

McCall M, Bolstad B, Irizarry R . Frozen robust multiarray analysis (fRMA). Biostatistics. 2010; 11(2):242-53. PMC: 2830579. DOI: 10.1093/biostatistics/kxp059. View

15.

Moon A, Yong H, Song J, Cukovic D, Salagrama S, Kaplan D . Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res. 2008; 6(10):1544-53. DOI: 10.1158/1541-7786.MCR-08-0189. View

16.

Srikrishna G . S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun. 2011; 4(1):31-40. PMC: 3250655. DOI: 10.1159/000330095. View

17.

Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S . RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat. 2013; 142(2):297-309. DOI: 10.1007/s10549-013-2737-1. View

18.

Bines J, Earl H, Buzaid A, Saad E . Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Ann Oncol. 2014; 25(6):1079-85. DOI: 10.1093/annonc/mdu007. View

19.

Fine J, Chen P, Mesci A, Allan D, Gasser S, Raulet D . Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res. 2010; 70(18):7102-13. PMC: 3108335. DOI: 10.1158/0008-5472.CAN-10-1316. View

20.

De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26(1):44-53. DOI: 10.1200/JCO.2007.11.3787. View